arrow
E

Els Van Nieuwenhuysen

KU Leuven
H指数:37
被引数:5,216

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-term efficacy and safety of avutometinib plus defactinib in recurrent low-grade serous ovarian cancer: Results of a 2-year follow-up of ENGOT-OV60/GOG-3052/RAMP 201

奥拉帕尼联合达芬钦在复发性低级别浆液性卵巢癌中的长期疗效与安全性:ENGOT-OV60/GOG-3052/RAMP 201研究2年随访结果

2026-09-010
OAAI
Long-Term Young Adult Cancer Survivors with Ovarian Cancer: Subgroup Analysis of the Study “Expression VI–Carolin Meets HANNA–Holistic Analysis of Long-Term Survival with Ovarian Cancer”: The International NOGGO, ENGOT, and GCIG Survey

长期年轻成年卵巢癌幸存者:研究“Expression VI–Carolin Meets HANNA–Holistic Analysis of Long-Term Survival with Ovarian Cancer”的亚组分析:国际NOGGO、ENGOT和GCIG调查

Cancers
IF4.4
2026-04-080
OAAI
GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer

GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301:一项评估阿伏莫替尼联合达法他尼与研究者选择治疗方案相比,在复发性低级别浆液性卵巢癌患者中的随机III期试验

2025-04-190
OAAI
Durvalumab Plus Carboplatin/Paclitaxel Followed By Durvalumab As First-Line Treatment For Endometrial Cancer: Patient-Reported Outcomes In The DUO-E/GOG-3041/ENGOT-EN10 Intent-To-Treat And Mismatch Repair Deficient Populations

度伐利尤单抗联合卡铂/紫杉醇后序贯度伐利尤单抗治疗子宫内膜癌的一线治疗:DUO-E/GOG-3041/ENGOT-EN10研究中的意向性治疗人群和错配修复缺陷人群的患者报告结局

2025-02-010
PRE
Durvalumab Plus Carboplatin/Paclitaxel Followed By Durvalumab Plus Olaparib As First-Line Treatment For Endometrial Cancer: Patient-Reported Outcomes In The DUO-E/GOG-3041/ENGOT-EN10 Intent-To-Treat And Mismatch Repair Proficient Populations

度伐利尤单抗联合卡铂/紫杉醇后接度伐利尤单抗联合奥拉帕利作为子宫内膜癌的一线治疗:DUO-E/GOG-3041/ENGOT-EN10研究的全分析集和错配修复功能正常人群的患者报告结局

2025-02-010
PRE
Durvalumab Plus Carboplatin/Paclitaxel Followed By Durvalumab With/Without Olaparib In Endometrial Cancer: Exploratory Analyses Of Histology, Biomarker Heterogeneity And Efficacy In The DUO-E Mismatch Repair Proficient Subpopulation

Durvalumab联合卡铂/紫杉醇后序贯Durvalumab联合或不联合奥拉帕利在子宫内膜癌中的探索性分析:DUO-E研究错配修复 proficient 亚人群的组织学、生物标志物异质性和疗效分析

2025-02-010
PRE
Chemotherapy With Or Without Pembrolizumab Followed By Maintenance With Olaparib Or Placebo For First-Line Treatment Advanced BRCA Non-Mutated Epithelial Ovarian Cancer: Results From The Randomized Phase 3 ENGOT-OV43/GOG-3036/KEYLYNK-001 Study

化疗联合或不联合帕博利珠单抗,随后接受奥拉帕尼或安慰剂维持治疗,用于一线治疗晚期BRCA未突变上皮性卵巢癌:来自随机III期ENGOT-OV43/GOG-3036/KEYLYNK-001研究的结果

2025-02-010
PRE
Phase II randomized study of dostarlimab alone or with bevacizumab versus non-platinum chemotherapy in recurrent gynecological clear cell carcinoma (DOVE/APGOT-OV7/ENGOT-ov80)

Dodarlimab单独或联合贝伐单抗与非铂类化疗在复发性妇科透明细胞癌中的II期随机研究 (DOVE/APGOT-OV7/ENGOT-ov80)

2025-01-010
PRE
Integrative multi-omics analyses to identify the genetic and functional mechanisms underlying ovarian cancer risk regions

整合多组学分析以确定卵巢癌风险区域的遗传和功能机制

2024-06-016
PRE
innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator′s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer
2023-10-0121
OA
Ubamatamab (MUC16xCD3 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study

Ubamatamab (MUC16xCD3双特异性抗体) 联合cemiplimab (anti-PD-1抗体) 治疗复发性卵巢癌: I期剂量递增研究

2023-10-013
OA
PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial
2023-07-0111
PRE
Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial)
CANCER
IF5.1
2022-06-1718
OAAI